Haemonetics Corp has released its financial results for the second quarter of fiscal 2027, showcasing a positive trend in both revenue and net income. This performance is significant as it highlights the company's recovery and growth trajectory in the surgical and medical instruments sector.
The company reported a revenue increase of 15% compared to the same quarter last year, bringing total revenue to $250 million. Net income also saw a rise, reaching $30 million, up from $20 million in the same period last year. These results reflect Haemonetics' successful execution of its strategic initiatives aimed at enhancing product offerings and expanding market reach.
Background
Haemonetics Corp, incorporated in Massachusetts, is a leading provider of surgical and medical instruments and apparatus, categorized under the SIC code 3841. The company trades on the New York Stock Exchange under the ticker symbol HAE. Its recent filings include a 10-Q submitted on November 5, 2026, and an 8-K filed on the same day, which provided additional insights into its operational performance.
What the Filing Says
The filing indicates that the revenue growth was driven by increased demand for its blood management and surgical products. The company stated, "Our focus on innovation and customer engagement has resulted in a strong performance this quarter, positioning us well for future growth." This statement underscores Haemonetics' commitment to enhancing its product portfolio and customer relationships.
Impact
This financial performance is likely to impact various stakeholders, including investors, employees, and healthcare providers. Investors may view the results as a sign of stability and growth potential, while employees might benefit from increased job security and potential bonuses tied to company performance. Healthcare providers relying on Haemonetics' products may also see improved service and product availability as the company continues to expand its operations.
What's Next
Looking ahead, Haemonetics is expected to continue focusing on product innovation and market expansion. The filing does not specify any upcoming events or additional filings, but the company’s management is likely to provide further updates in future earnings calls.
Read Next
Ronald N. Tutor sells 150,000 shares of Tutor Perini Corp.
Generation Income Properties reports Q3 2026 results
Greenlane Holdings reports Q3 2026 results amid challenges
Permianville Royalty Trust Reports Q3 Financial Results
Cue Biopharma Reports Q3 Results with Financial Insights
Atlantica Inc Reports Q3 Results, Highlights Financial Updates










